BrainStorm Cell Therapeutics Faces Major Setback
BrainStorm Cell Therapeutics Inc. (BCLI) shares plummeted by 42.74% to $0.67 in after-hours trading on Friday following the company's announcement of its voluntary delisting from the Nasdaq Capital Market. This significant drop has raised concerns among investors and the larger biotechnology community.
The Delisting Announcement
BrainStorm officially announced it received a formal notification from The Nasdaq Stock Market LLC indicating that its common stock would be suspended from trading at market open on Friday. The delisting is mainly due to the company's failure to comply with the Nasdaq Listing Rule 5550(b)(1), which stipulates that companies must maintain a minimum amount of shareholder equity.
Year-to-Date Performance
Year-to-date, BrainStorm's stock has witnessed a decline of approximately 45.33%. The stock closed at $1.17 on Thursday prior to the after-hours selloff, reflecting the downward trend this year. Following the delisting, the company has gained approval to trade on the OTCQB Venture Market, utilizing the same BCLI ticker symbol effective immediately.
CEO's Assurance to Stakeholders
In a statement, CEO Chaim Lebovits reassured shareholders and the patient community saying, “While this delisting from Nasdaq is a challenging outcome, we want to assure our shareholders and the patient community that it does not alter our core mission.” BrainStorm expressed its ongoing commitment to developing its lead investigational therapy, NurOwn, which targets amyotrophic lateral sclerosis (ALS).
Continued Focus on ALS Treatment
BrainStorm's operations and research endeavors remain intact despite the delisting, reinforcing the company's commitment to its innovative treatments. The proprietary NurOwn platform employs autologous adult stem cells to produce neurotrophic factor-secreting cells designed specifically for ALS patients. This therapy holds Orphan Drug designation from both the FDA and the European Medicines Agency, highlighting its potential therapeutic value.
Planned Clinical Trials
Moving forward, BrainStorm completed a Phase 3 ALS trial and plans to initiate a Phase 3b trial under a Special Protocol Assessment agreement with the FDA. Additionally, the company has undertaken a Phase 2 trial for progressive multiple sclerosis, backed by a grant from the National MS Society.
Market Impact and Investment Opportunities
Market analysts view the recent events as pivotal for BrainStorm. Despite the setback, the company's short-term price trend remains positive according to recent evaluations. Investors are advised to remain vigilant regarding future developments and the company's plans moving forward.
Frequently Asked Questions
What caused BrainStorm's stock to drop significantly?
The stock dropped significantly due to the announcement of its voluntary delisting from the Nasdaq Capital Market following non-compliance with specific listing rules.
What is the core mission of BrainStorm Cell Therapeutics?
BrainStorm is focused on developing therapies for neurodegenerative diseases, particularly through its lead investigational therapy for ALS known as NurOwn.
Where can BrainStorm shares be traded after the delisting?
Following the delisting from Nasdaq, BrainStorm shares are now trading on the OTCQB Venture Market under the same BCLI ticker symbol.
What does the CEO say about the company's future?
CEO Chaim Lebovits stated that the core mission of the company remains unchanged despite the delisting, ensuring continued dedication to ALS treatment.
What regulatory designations has NurOwn received?
NurOwn has received Orphan Drug designation from both the FDA and the European Medicines Agency, indicating its significant potential for patients with ALS.
